Patents by Inventor Andrew Mark Sharkey

Andrew Mark Sharkey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030186907
    Abstract: Disclosed is a method of altering one or more characteristics of at least some of the cells of the reproductive tract of a mammalian individual by the introduction into said cells of a nucleic acid, together with a composition comprising nucleic acid, for use in the method.
    Type: Application
    Filed: September 24, 2002
    Publication date: October 2, 2003
    Applicant: Cambridge University Technical Services Limited
    Inventors: David Stephen Charnock-Jones, Stephen Kevin Smith, Andrew Mark Sharkey, Robert Brian Heap
  • Patent number: 6472374
    Abstract: Disclosed is a method of altering one or more characteristics of at least some of the cells of the reproductive tract of a mammalian individual by the introduction into said cells of a nucleic acid, together with a composition comprising nucleic acid, for use in the method.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: October 29, 2002
    Assignee: Cambridge University Technical Services Limited
    Inventors: David Stephen Charnock-Jones, Stephen Kevin Smith, Andrew Mark Sharkey, Robert Brian Heap
  • Patent number: 6177556
    Abstract: SCF which includes the following C-terminal sequence: Glu Ile Cys Ser Leu Leu Ile Gly Leu Thr Ala Tyr Lys Glu Leu Ser Leu Pro Lys Arg Lys Glu Thr Cys Arg Ala Ile Gln His Pro Arg Lys Asp or a C-terminal sequence which is substantially homologous thereto and its use in medicine, particularly in ensuring the correct development of pre-implantation embryos.
    Type: Grant
    Filed: July 31, 1997
    Date of Patent: January 23, 2001
    Assignee: Applied Research Systems ARS Holdings N.V.
    Inventors: Andrew Mark Sharkey, Stephen Kevin Smith, Kimberley Anne Dellow
  • Patent number: 6011003
    Abstract: Disclosed is an altered, soluble form of the FLT polypeptide being capable of binding to VEGF and thereby exerting an inhibitory effect thereon, the polypeptide comprising five or fewer complete immunoglobulin-like domains, together with pharmaceutical compositions comprising the polypeptide, and various uses thereof.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: January 4, 2000
    Assignee: Metris Therapeutics Limited
    Inventors: David Stephen Charnock-Jones, Christine Ann Boocock, Andrew Mark Sharkey, Stephen Kevin Smith